Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Other financing activities (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Other financing activities for 14 consecutive years, with $134000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities changed N/A to $134000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $209000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $4.1 million for FY2025, N/A changed from the prior year.
  • Other financing activities hit $134000.0 in Q4 2025 for Integra Lifesciences Holdings, up from $75000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $7.6 million in Q1 2023 to a low of $75000.0 in Q3 2025.
  • Historically, Other financing activities has averaged $1.7 million across 3 years, with a median of $249000.0 in 2021.